D.E. Shaw & Co
CLDI icon

D.E. Shaw & Co’s Calidi Biotherapeutics CLDI Stock Holding History

D.E. Shaw & Co’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,834
Closed -$8.15M – 5227
2022
Q2 		$8.15M Buy
6,834
+3
+0% +$3.57K 0.01% 1585
2022
Q1 		$8.11M Buy
6,831
+33
+0.5% +$39K 0.01% 1803
2021
Q4 		$8.02M Buy
+6,798
New +$8.01M 0.01% 1890

Other funds holding CLDI

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

D.E. Shaw & Co's CLDI Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Calidi Biotherapeutics (CLDI) in Q3 2022, closing a stake of 6,834 shares — an estimated $8.15M sold.

D.E. Shaw & Co first reported a position in CLDI in Q4 2021 and held it in 3 quarters. The position peaked at $8.15M in Q2 2022. 21 funds tracked by Wall St. Rank hold CLDI as of Q3 2022.

  • D.E. Shaw & Co reported no remaining Calidi Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 6,834 Calidi Biotherapeutics shares in Q3 2022, an estimated $8.15M.
  • D.E. Shaw & Co first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 3 quarters.
  • D.E. Shaw & Co's Calidi Biotherapeutics position peaked at $8.15M in Q2 2022.
  • 21 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.